We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBRV
76
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$164K 0.25%
80
+20
+33% +$46.9K
LJPC
77
DELISTED
La Jolla Pharmaceutical Company
LJPC
$159K 0.24%
+4,560
New +$147K
SRPT icon
78
CALL
Sarepta Therapeutics
SRPT
$1.82B
$157K 0.24%
24,300
+8,000
+49% +$320K
KHC icon
79
Kraft Heinz
KHC
$30.7B
$155K 0.23%
+2,000
New +$167K
MDLZ icon
80
PUT
Mondelez International
MDLZ
$78.3B
$148K 0.22%
73,000
+8,000
+12% +$340K
GILD icon
81
PUT
Gilead Sciences
GILD
$167B
$147K 0.22%
+100,000
New +$7.65M
OTIC
82
DELISTED
Otonomy, Inc.
OTIC
$147K 0.22%
45,101
-13,306
-23% -$179K
ZYNE
83
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$146K 0.22%
17,500
+15,000
+600% +$159K
BLUE
84
PUT
DELISTED
bluebird bio
BLUE
$143K 0.22%
+1,004
New +$1.4M
FL
85
DELISTED
Foot Locker
FL
$141K 0.21%
+4,000
New +$168K
ABBV icon
86
PUT
AbbVie
ABBV
$450B
$135K 0.2%
50,000
+40,000
+400% +$3.04M
CCEP icon
87
CALL
Coca-Cola Europacific Partners
CCEP
$46.5B
$133K 0.2%
33,000
– –
GDX icon
88
VanEck Gold Miners ETF
GDX
$21.8B
$132K 0.2%
+5,765
New +$133K
REGN icon
89
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
$125K 0.19%
4,500
-8,500
-65% -$4.04M
DXCM icon
90
DexCom
DXCM
$29.6B
$122K 0.18%
+10,000
New +$177K
POT
91
DELISTED
Potash Corp Of Saskatchewan
POT
$121K 0.18%
6,300
-33,780
-84% -$602K
NKE icon
92
PUT
Nike
NKE
$64.9B
$116K 0.17%
+20,400
New +$1.15M
FCSC
93
DELISTED
Fibrocell Science Inc.
FCSC
$116K 0.17%
+7,600
New +$123K
CLVS
94
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$112K 0.17%
49,600
-15,000
-23% -$1.19M
CALM icon
95
CALL
Cal-Maine
CALM
$4.2B
$105K 0.16%
+45,000
New +$1.68M
AKBA icon
96
PUT
Akebia Therapeutics
AKBA
$359M
$104K 0.16%
+30,000
New +$461K
CMRX
97
CALL
DELISTED
Chimerix, Inc.
CMRX
$99K 0.15%
+150,000
New +$738K
LOXO
98
CALL
DELISTED
Loxo Oncology, Inc
LOXO
$97K 0.15%
+10,000
New +$777K
PTCT icon
99
CALL
PTC Therapeutics
PTCT
$6.52B
$95K 0.14%
+53,000
New +$1.04M
ACAD icon
100
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
$94K 0.14%
10,900
+700
+7% +$22.8K
2 3
4
5 6

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.